AJOVista LLC Invests $51,000 in Astria Therapeutics, Inc. (NASDAQ:ATXS)

AJOVista LLC bought a new stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 6,636 shares of the biotechnology company’s stock, valued at approximately $51,000.

Separately, Jump Financial LLC purchased a new position in Astria Therapeutics in the third quarter valued at $111,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Stock Performance

ATXS stock opened at $9.73 on Monday. Astria Therapeutics, Inc. has a 52-week low of $4.26 and a 52-week high of $16.90. The stock’s 50 day moving average is $12.62 and its two-hundred day moving average is $9.44.

Astria Therapeutics (NASDAQ:ATXS) last posted its quarterly earnings results on Monday, March 4th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.08). As a group, equities research analysts predict that Astria Therapeutics, Inc. will post -1.55 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Jefferies Financial Group raised their price target on shares of Astria Therapeutics from $22.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, March 25th. Wedbush reiterated an “outperform” rating and issued a $17.00 price target on shares of Astria Therapeutics in a research note on Tuesday, March 26th. Finally, HC Wainwright reduced their price target on shares of Astria Therapeutics from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, April 23rd.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.